JP2009524691A5 - - Google Patents

Download PDF

Info

Publication number
JP2009524691A5
JP2009524691A5 JP2008552564A JP2008552564A JP2009524691A5 JP 2009524691 A5 JP2009524691 A5 JP 2009524691A5 JP 2008552564 A JP2008552564 A JP 2008552564A JP 2008552564 A JP2008552564 A JP 2008552564A JP 2009524691 A5 JP2009524691 A5 JP 2009524691A5
Authority
JP
Japan
Prior art keywords
alkyl
aryl
heterocyclyl
cycloalkyl
heterocyclylalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2008552564A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009524691A (ja
Filing date
Publication date
Priority claimed from US11/625,889 external-priority patent/US7615556B2/en
Application filed filed Critical
Publication of JP2009524691A publication Critical patent/JP2009524691A/ja
Publication of JP2009524691A5 publication Critical patent/JP2009524691A5/ja
Withdrawn legal-status Critical Current

Links

JP2008552564A 2006-01-27 2007-01-25 ケモカインレセプター活性のモジュレータとしてのピペラジニル誘導体 Withdrawn JP2009524691A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US76305106P 2006-01-27 2006-01-27
US11/625,889 US7615556B2 (en) 2006-01-27 2007-01-23 Piperazinyl derivatives as modulators of chemokine receptor activity
PCT/US2007/061014 WO2007087585A1 (en) 2006-01-27 2007-01-25 Piperazinyl derivatives as modulators of chemokine receptor activity

Publications (2)

Publication Number Publication Date
JP2009524691A JP2009524691A (ja) 2009-07-02
JP2009524691A5 true JP2009524691A5 (enExample) 2010-03-11

Family

ID=37969746

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008552564A Withdrawn JP2009524691A (ja) 2006-01-27 2007-01-25 ケモカインレセプター活性のモジュレータとしてのピペラジニル誘導体

Country Status (7)

Country Link
US (2) US7615556B2 (enExample)
EP (1) EP1973880B1 (enExample)
JP (1) JP2009524691A (enExample)
KR (1) KR20080090538A (enExample)
AU (1) AU2007208031A1 (enExample)
NO (1) NO20083358L (enExample)
WO (1) WO2007087585A1 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007070660A2 (en) 2005-12-13 2007-06-21 President And Fellows Of Harvard College Scaffolds for cell transplantation
US7601844B2 (en) * 2006-01-27 2009-10-13 Bristol-Myers Squibb Company Piperidinyl derivatives as modulators of chemokine receptor activity
EP2173714B9 (en) * 2007-07-24 2013-04-10 Bristol-Myers Squibb Company Piperidine derivatives as modulators of chemokine receptor activity
JP2010534669A (ja) * 2007-07-24 2010-11-11 ブリストル−マイヤーズ スクイブ カンパニー ケモカイン受容体活性のモジュレーターとしての非環式誘導体
CA2715460C (en) 2008-02-13 2020-02-18 President And Fellows Of Harvard College Continuous cell programming devices
WO2009111607A1 (en) 2008-03-07 2009-09-11 Bristol-Myers Squibb Company Hydroxyalkanyl amides as modulators of chemokine receptor activity
JP5746612B2 (ja) * 2008-03-19 2015-07-08 オーリムメッド・ファルマ・インコーポレーテッド 中枢神経系疾患および障害の治療に有効な新規化合物
US10793515B2 (en) 2008-03-19 2020-10-06 Aurimmed Pharma, Inc. Compounds advantageous in the treatment of central nervous system diseases and disorders
US20210130285A1 (en) 2008-03-19 2021-05-06 Aurimmed Pharma, Inc. Novel compounds advantageous in the treatment of central nervous system diseases and disorders
TWI433838B (zh) 2008-06-25 2014-04-11 必治妥美雅史谷比公司 作為趨化因子受體活性調節劑之六氫吡啶衍生物
AU2010278702C1 (en) * 2009-07-31 2016-07-14 Forsyth Dental Infirmary For Children Programming of cells for tolerogenic therapies
US8642622B2 (en) 2010-06-16 2014-02-04 Bristol-Myers Squibb Company Piperidinyl compound as a modulator of chemokine receptor activity
HRP20200310T1 (hr) 2010-10-06 2020-08-21 President And Fellows Of Harvard College Hidrogelovi koji stvaraju pore pogodni za injekcije, namijenjeni staničnim terapijama na bazi materijala
US9675561B2 (en) 2011-04-28 2017-06-13 President And Fellows Of Harvard College Injectable cryogel vaccine devices and methods of use thereof
KR20130064689A (ko) * 2011-12-08 2013-06-18 삼성전자주식회사 광굴절 복합체, 상기 광굴절 복합체를 포함하는 공간광 변조기 및 홀로그램 디스플레이 장치
FR2985256B1 (fr) * 2011-12-30 2016-03-04 Pitty Marc Henry Derives piperazinyles pour le traitement de cancers
ES2773895T3 (es) 2012-04-16 2020-07-15 Harvard College Composiciones de sílice mesoporosa para modular las respuestas inmunitarias
US8716235B2 (en) 2012-04-18 2014-05-06 Albert Einstein College Of Medicine Of Yeshiva University Method for inhibiting metastasis by using anti-CCL3 antibodies
US20160214967A1 (en) * 2013-09-30 2016-07-28 The University Of Tokyo Activator of adiponectin receptor
CN107073090A (zh) 2014-04-30 2017-08-18 哈佛学院董事会 结合的疫苗装置和杀死癌细胞的方法
WO2016123573A1 (en) 2015-01-30 2016-08-04 President And Fellows Of Harvard College Peritumoral and intratumoral materials for cancer therapy
US11150242B2 (en) 2015-04-10 2021-10-19 President And Fellows Of Harvard College Immune cell trapping devices and methods for making and using the same
WO2017136837A1 (en) 2016-02-06 2017-08-10 President And Fellows Of Harvard College Recapitulating the hematopoietic niche to reconstitute immunity
AU2017295704B2 (en) 2016-07-13 2023-07-13 President And Fellows Of Harvard College Antigen-presenting cell-mimetic scaffolds and methods for making and using the same
CN110418651A (zh) 2016-08-02 2019-11-05 哈佛学院院长等 用于调节免疫应答的生物材料
WO2020061129A1 (en) 2018-09-19 2020-03-26 President And Fellows Of Harvard College Compositions and methods for labeling and modulation of cells in vitro and in vivo
JP2022514568A (ja) 2018-12-17 2022-02-14 プレジデント アンド フェローズ オブ ハーバード カレッジ 免疫系のモジュレーションのための生物工学的スキャフォールドおよびその使用
JP2022549270A (ja) 2019-09-23 2022-11-24 プレジデント アンド フェローズ オブ ハーバード カレッジ バイオマテリアルベースの無抗原ワクチンおよびその使用

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9104656D0 (en) 1991-03-05 1991-04-17 Zambeletti Spa L Pharmaceuticals
DE4243858A1 (de) 1992-12-23 1994-06-30 Thomae Gmbh Dr K Aminosäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
US5459151A (en) 1993-04-30 1995-10-17 American Home Products Corporation N-acyl substituted phenyl piperidines as bronchodilators and antiinflammatory agents
US5777112A (en) 1994-06-13 1998-07-07 Merck & Co., Inc Piperazine compounds promote release of growth hormone
CA2226740A1 (en) * 1995-07-13 1997-01-30 Mitsuyoshi Azuma Piperazine derivative and its uses
FR2740134B1 (fr) * 1995-10-18 1998-01-09 Pf Medicament Derives d'amines cycliques d'aryl-piperazines, leur preparation et les compositions pharmaceutiques les contenant
ATE239698T1 (de) * 1995-10-25 2003-05-15 Senju Pharma Co Angiogenese hemmer
EP0944388A4 (en) 1996-04-03 2001-08-16 Merck & Co Inc INHIBITORS OF FARNESYL PROTEIN TRANSFERASE
WO1998017625A1 (en) 1996-10-22 1998-04-30 Daiichi Pharmaceutical Co., Ltd. Novel remedies for infectious diseases
US5847148A (en) 1997-04-10 1998-12-08 Pharmacia & Upjohn Company Thiadiazole derivatives useful for the treatment of diseases related to connective tissue degradation
ZA987385B (en) 1997-08-19 2000-04-18 Lilly Co Eli Growth hormone secretagogues.
ZA987383B (en) 1997-08-19 2000-02-17 Lilly Co Eli Treatment of congestive heart failure with growth hormone secretagogues.
WO1999011658A1 (en) * 1997-08-29 1999-03-11 Proteus Molecular Design Ltd. Meta-benzamidine derivatives as serin protease inhibitors
HUP0101419A3 (en) * 1998-04-16 2002-08-28 Texas Biotechnology Corp Houst Compounds that inhibit the binding of integrins to their receptors and pharmaceutical compositions containing them
US6391865B1 (en) 1999-05-04 2002-05-21 Schering Corporation Piperazine derivatives useful as CCR5 antagonists
WO2000074679A1 (en) 1999-06-04 2000-12-14 Merck & Co., Inc. Substituted piperidines as melanocortin-4 receptor agonists
DE19939910A1 (de) 1999-08-23 2001-03-01 Morphochem Ag Neue Verbindungen, die Tryptase-Aktivität hemmen
DE10041402A1 (de) * 2000-08-23 2002-03-14 Morphochem Ag Neue Verbindungen, die Faktor Xa-Aktivität inhibieren
AUPQ386899A0 (en) * 1999-11-04 1999-11-25 Fujisawa Pharmaceutical Co., Ltd. Peptide compounds
JP2001354657A (ja) 2000-06-09 2001-12-25 Sds Biotech:Kk 置換ピペラジン誘導体及び農園芸用殺菌剤
DE10056312A1 (de) * 2000-11-14 2002-05-16 Bayer Ag Substituierte Amidoalkyluracile und ihre Verwendung
US6861424B2 (en) * 2001-06-06 2005-03-01 Schering Aktiengesellschaft Platelet adenosine diphosphate receptor antagonists
WO2003007949A1 (en) 2001-07-18 2003-01-30 Merck & Co., Inc. Bridged piperidine derivatives as melanocortin receptor agonists
US6977264B2 (en) 2001-07-25 2005-12-20 Amgen Inc. Substituted piperidines and methods of use
MY141661A (en) 2001-09-06 2010-05-31 Schering Corp 17b-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
CA2468658C (en) * 2001-11-30 2009-04-14 Schering Corporation [1,2,4]-triazole bicyclic adenosine a2a receptor antagonists
KR20040068317A (ko) 2001-12-20 2004-07-30 오에스아이 파마슈티컬스, 인코포레이티드 피리미딘 a₂b 선택성 길항 화합물, 그의 합성 방법 및용도
DE60236458D1 (de) 2001-12-20 2010-07-01 Osi Pharm Inc Pyrrolopyrimidin a2b selektive antagonistische verbindungen, deren synthese und verwendung
US7041681B2 (en) 2002-04-29 2006-05-09 Janssen Pharmaceutica N.V. Compounds as opioid receptor modulators
US20050256130A1 (en) 2002-06-12 2005-11-17 Chemocentryx, Inc. Substituted piperazines
GB0224917D0 (en) 2002-10-25 2002-12-04 Novartis Ag Organic compounds
CA2512886A1 (en) 2003-02-28 2004-09-10 Galderma Research & Development, S.N.C. Ligands that modulate lxr-type receptors
EP1633737A1 (en) 2003-06-13 2006-03-15 Schering Aktiengesellschaft Quinolyl amide derivatives as ccr-5 antagonists
GB0315203D0 (en) 2003-06-28 2003-08-06 Celltech R&D Ltd Chemical compounds
KR100844593B1 (ko) * 2004-03-09 2008-07-07 내셔날 헬스 리서치 인스티튜트 피롤리딘 화합물
GB0412468D0 (en) 2004-06-04 2004-07-07 Astrazeneca Ab Chemical compounds
US7723360B2 (en) 2004-08-06 2010-05-25 Boehringer Ingelheim International Gmbh Alkyl-and piperidine-substituted benzimidazole derivatives

Similar Documents

Publication Publication Date Title
JP2019034943A5 (enExample)
JP2016500107A5 (ja) グルタミナーゼ阻害剤およびその使用方法
JP2015508092A5 (enExample)
JP2015502387A5 (enExample)
JP2008511601A5 (enExample)
JP2010535180A5 (enExample)
JP2018150331A5 (enExample)
JP2008513516A5 (enExample)
JP2017533968A5 (enExample)
JP2018518537A5 (enExample)
JP2016534134A5 (enExample)
JP2022533069A5 (enExample)
JP2009515988A5 (enExample)
JP2013516473A5 (enExample)
JP2013500986A5 (enExample)
JP2006513268A5 (ja) アンタゴニスト活性を有するベンゾアゾリルピペラジン誘導体
JP2010526146A5 (enExample)
JP2007500715A5 (enExample)
JP2008510828A5 (enExample)
JP2009542595A5 (enExample)
JP2017509689A5 (enExample)
JP2012522847A5 (enExample)
JP2017536395A5 (enExample)
JP2013526494A5 (enExample)
JP2009543795A5 (enExample)